Ensysce Biosciences Expands Global Opioid Patent Portfolio
~ TAAP™ and MPAR® technologies extended across opioid products to advance safer pain treatment ~ SAN DIEGO, CALIFORNIA / ACCESS...
Clinical Trial
Aspire Biopharma’s Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign
New streamlined, mobile-optimized shopping experience, allows consumers to purchase BUZZ BOMB™ directly, access exclusive promotions and engage with the brand...
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
-Initiation of phase 1 portion of the trial planned in 2H 2026 -Phase 2 portion of the trial will initiate...
Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit
Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused...
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19th 2025 FDA Ruling Next-Generation EB613...
Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103)
The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026 LONDON and PHILADELPHIA, Jan....
Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use
Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, reflecting a maturing and expanding...
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
Interim analyses on track for the first and second half of 2026SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE)...
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
The QIDP designation will ensure at least 10 years of market exclusivity for SCY-247 following approval Recent articles highlight the...
DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE
Event Sponsored by LIXTE Biotechnology Holdings,Developer of Breakthrough Cancer Therapies Atlanta, GA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Inspired by...
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
California joins 23 other states eligible to receive free neffy® (epinephrine nasal spray) at schools SAN DIEGO, Jan. 21, 2026...
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL
SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission...
LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage...
BrainsWay Announces Draft Coverage Policy from Highmark® for Accelerated Deep TMS™
New draft policy from Highmark Blue Cross Blue Shield extends to both adolescent and adult depression patientsBURLINGTON, Mass. and JERUSALEM,...
Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026
MELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the...
Skye Bioscience to Present Poster at Keystone Obesity Conference
SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on...
Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer
Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA® while...
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
Stockholders to also receive two contingent value rights valued at $1 per share, each entitled to be received upon the...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
Company Announcement Net sales of DARZALEX® in 2025 totaled USD 14,351 millionGenmab receives royalties on worldwide net sales from Johnson...
FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study
HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Hopstem Biotechnology Inc. (hereinafter referred to as "Hopstem"), a company dedicated to the...